Dermatology Department, Paul Sabatier University, Toulouse, France.
J Eur Acad Dermatol Venereol. 2012 May;26 Suppl 3:61-7. doi: 10.1111/j.1468-3083.2012.04525.x.
Treatment adherence has been recognized as an important issue in the management of chronic diseases such as psoriasis.
The aim of this work was to analyse data about topical treatment adherence in psoriasis.
Systematic literature review (62 references) between 1980 and 2011 (database: PubMed, Embase and Cochrane; Mesh keywords: Patient Compliance [Mesh] OR Medication Adherence [Mesh] AND Psoriasis [Mesh]; limits: date of publication >1980, humans subjects, written in French or English, aged ≥ 19 years). Two parameters were evaluated: (i) the ratio of number of product applications performed vs. number of applications expected according to physician recommendations, (ii) the ratio of amount of product used vs. amount of product prescribed.
A total of 22 studies were selected. Nine studies reported on the frequency of topical treatment application in a real world setting. Five studies showed a frequency of applications varying between 50% and 60% of those expected. Because of the high variability in medication adherence assessment methods, the data could not be combined. Twelve articles reported on the frequency of topical treatment application in randomized controlled trials with adherence varying between 55% and 100%. Concerning the amount of product use, four studies showed patients applied between 35% and 72% of the recommended dose during a treatment period of 14 days to 8 weeks. The most frequently mentioned reasons for non-adherence to topical treatment were low efficacy, time consumption and poor cosmetic characteristics of topical agents. Patients experiencing adherence issues were significant younger, were men, had younger age at onset of psoriasis and had a higher self-assessed severity. To improve adherence, the following strategies were suggested: to give patients information about psoriasis, to recognize social impact, to give written instructions for use such as a care plan, to explain side effects of topical therapies, to choose treatment and its cosmetic properties in agreement with the patient.
Literature data about topical treatment adherence are heterogeneous and scarce. They confirm the limited topical treatment adherence in psoriasis in real life, much lower than what is reported in randomized controlled trials. Therapeutic education and clear instructions on the use of topical agents are necessary to improve adherence. Studies are needed to identify predictors of limited adherence and to identify interventions improving adherence to topical medications in psoriasis.
治疗依从性已被认为是银屑病等慢性病管理中的一个重要问题。
本研究旨在分析银屑病局部治疗依从性的数据。
系统文献回顾(1980 年至 2011 年共 62 篇参考文献)(数据库:PubMed、Embase 和 Cochrane;Mesh 关键词:患者依从性[Mesh]或药物依从性[Mesh]和银屑病[Mesh];限制:出版日期>1980 年,人类研究对象,用法语或英语书写,年龄≥19 岁)。评估了两个参数:(i)根据医生建议,实际应用产品的次数与预期应用次数之比,(ii)使用的产品量与规定的产品量之比。
共选择了 22 项研究。9 项研究报告了真实环境下局部治疗的应用频率。5 项研究显示,应用频率在预期的 50%至 60%之间变化。由于药物依从性评估方法的高度变异性,数据无法合并。12 篇文章报告了随机对照试验中局部治疗应用的频率,依从性在 55%至 100%之间变化。关于使用产品的数量,四项研究显示,在 14 天至 8 周的治疗期间,患者应用了推荐剂量的 35%至 72%。最常提到的不遵守局部治疗的原因是疗效低、时间消耗和局部药物的美容特性差。出现依从性问题的患者明显更年轻,是男性,银屑病发病年龄更小,自我评估的严重程度更高。为了提高依从性,提出了以下策略:为患者提供有关银屑病的信息,认识社会影响,提供书面使用说明,如护理计划,解释局部治疗的副作用,选择治疗方法及其美容特性与患者达成一致。
有关局部治疗依从性的文献数据具有异质性且稀少。它们证实了现实生活中银屑病局部治疗的依从性有限,远低于随机对照试验报告的水平。需要进行研究以确定有限依从性的预测因素,并确定改善银屑病局部药物依从性的干预措施。